Biomics Biotechnologies Co., Ltd. (Biomics) was founded by Dr. York Zhu, an American scientist, in February 2006. Since its foundation, Biomics has grown to an Asian leading RNAi therapeutical technologies company with combined technology platforms of full-sites siRNA library, drug targets screening and identification, siRNA structure modification and drug delivery systems.

The Biomics' competence lies on its 3 centers: RNAi Therapeutics R&D Center, Life Science Center and Chemical Synthesis Center.

Biomics' RNAi Therapeutics R&D Center, including a siRNA drug R&D lab in Silicon Valley USA and a pilot R&D base in Nantong, China, is our core value. With the support of Biomics’ other 2 bases, Life Science Center and Chemical Synthesis Center, it can make Biomics to continue its innovation on siRNA drug development.

Biomics' Life Science Center focuses on Molecular biology products development; provides life science lab services and life sciences reagents

Biomics' Chemical Synthesis Center owns full set of technologies of DNA and RNA synthesis. It also has high volume siRNA synthesis capacity .

As Biomics' 2 bases, Life Science Center and Chemical Synthesis Center provide support of RNAi therapeutics research not only to to Biomics’ internal research, but also to Biomics’ partners and Biomics’ customers.

Biomics hopes to work together with all people and companies from the world to create a healthy world by continuously innovating RNAi therapeutics.